Skip to main content
. 2023 Jun 1;6(8):e202301902. doi: 10.26508/lsa.202301902

Figure 4. Anti-miR-33 treatment with the GAN diet improves the lipid profile in the serum and liver.

Figure 4.

(A) Relative expression levels of Abca1, Cpt1a, and Crot in the livers of the indicated groups. n = 6–10 samples per group; *P < 0.05 and ***P < 0.001, one-way ANOVA with Tukey’s post hoc test. (B) Western blotting analysis of ABCA1, CPT1A, and CROT expression in the livers of the indicated groups. GAPDH was used as a loading control. n = 5 samples per group. (C) Densitometry of hepatic ABCA1, CPT1A, and CROT. n = 5 mice per group; *P < 0.05 and **P < 0.01, unpaired t test. (D) Total cholesterol, free cholesterol, and triglyceride levels in the livers of the indicated groups. n = 4–7 samples per group; **P < 0.01 and ***P < 0.001, one-way ANOVA with Tukey’s post hoc test. (E) Representative images of cholesterol crystals with and without a polarizing filter in the liver sections of the indicated groups. (F) Quantification of cholesterol crystal in the liver sections. n = 4–6 samples per group; **P < 0.01 and ***P < 0.001, one-way ANOVA with Tukey’s post hoc test.